Full Text
1. Indirect Treatment Comparison of Pembrolizumab Versus Standard-of-Care for Relapsed and Refractory Classical Hodgkin’s Lymphoma Using Time-Varying Hazard Ratios

Abstract

Authors

E Wu S Keeping K Chan A Mojebi A Balakumaran

Back to Volume 21, Supplemental S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×